Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with
cancer: Cancer Cell Skip to Main Content Advertisement Cancer Cell This journal offers …

SARS-CoV-2 vaccines are effective in preventing COVID-19. Patients with cancer are at
high risk for severe COVID-19 and are appropriately prioritized for vaccination. Several …

Immune responses following third COVID-19 vaccination are reduced in patients with
hematological malignancies compared to patients with solid cancer: Cancer Cell Skip to Main …

Patients with cancer, particularly those under active therapy, are at increased risk of
morbidity and mortality when infected with SARS-CoV-2 (Bakouny et al., 2020; Grivas et al …

Simple Summary Cancer patients undergoing active treatment may be more vulnerable to
COVID-19 due to the effects of the malignant disease and the anti-cancer treatment …

There is currently a critical need to determine the efficacy of SARS-CoV-2 vaccination for
immunocompromised patients. In this study, we determined the neutralizing antibody …

Abstract Coronavirus disease-19 (COVID-19) vaccine response data for patients with
hematologic malignancy, who carry high risk for severe COVID-19 illness, are incomplete. In …

Background It was shown that immunocompromised patients have significantly reduced
immunologic responses to COVID-19 vaccines. The immunogenicity of COVID-19 …

Patients with cancer are considered to be at high-risk for SARS-CoV-2 infection and severe
COVID-19 (Bakouny et al., 2020). Our ''SOAP-02''(Sars-CoV-2 fOr cAncer Patients) study has …

Published series on COVID-19 support the notion that patients with cancer are a particularly
vulnerable population. There is a confluence of risk factors between cancer and COVID-19 …